Rhumbline Advisers Ascendis Pharma A/S Put Options Transaction History
Rhumbline Advisers
- $109 Billion
- Q3 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ASND
# of Institutions
243Shares Held
58.8MCall Options Held
250KPut Options Held
377K-
Ra Capital Management, L.P. Boston, MA9.71MShares$1.23 Billion20.22% of portfolio
-
Westfield Capital Management CO LP Boston, MA5.13MShares$649 Million3.62% of portfolio
-
Avoro Capital Advisors LLC New York, NY4.99MShares$631 Million11.21% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI4.41MShares$558 Million1.03% of portfolio
-
Janus Henderson Group PLC London, X04.19MShares$530 Million0.33% of portfolio
About Ascendis Pharma A/S
- Ticker ASND
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,810,200
- Market Cap $7.06B
- Description
- Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...